Summary
Synthetic Biologics, Inc. (Synthetic Biologics), formerly Adeona Pharmaceuticals, Inc., is a biotechnology company that develops anti-infective biologics and drug candidates targeting infections and disease specific pathogens. The company develops synthetic biologic candidates including a series of monoclonal antibodies for the treatment of serious infectious diseases. Synthetic Biologics products find application in the treatment of relapsing-remitting multiple sclerosis, cognitive dysfunction in multiple sclerosis, C. difficile infection prevention, pertussis, acinetobacter infection and irritable bowel syndrome. The company has collaborations with academic and pharmaceutical companies. Synthetic Biologics is headquartered in Rockville, Maryland, United States.
Synthetic Biologics, Inc. (SYN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Synthetic Biologics Completes Acquisition Of C. difficile Infectious Disease Program Of Prev AbR 10
Partnerships 12
Intrexon Enters into Partnership with Synthetic Biologics 12
Synthetic Biologics Enters Into Agreement With Intrexon To Develop Monoclonal Antibodies For Infectious Diseases 13
Adeona Pharma Enters Into Co-Development Agreement With Intrexon 15
Adeona Pharma Enters Into Co-Development Agreement With Meda 17
Licensing Agreements 19
Synthetic Biologics Terminates Licensing Agreement with University of California 19
Synthetic Biologics Enters Into Licensing Agreement With Cedars-Sinai Medical Center 21
Equity Offering 23
Synthetic Biologics Raises USD46 Million in Public Offering of Shares 23
Synthetic Biologics to Raise USD20.7 Million in Private Placement of Units 25
Synthetic Biologics Completes Public Offering Of Shares For US$13.2 Million 27
Synthetic Biologics Completes Private Placement Of Common Stock For US$11 Million 28
Adeona Pharma Completes Private Placement Of Shares For US$3.5 Million 30
Adeona Pharma Completes Registered Direct Offering For US$4 Million 32
Adeona Pharma Completes Private Placement Of US$1 Million 34
Acquisition 36
Hartlab Acquires Adeona Clinical Lab From Synthetic Biologics 36
Synthetic Biologics, Inc. - Key Competitors 37
Key Employees 38
Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40
List of Tables
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Key Facts, 2014 1
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Synthetic Biologics, Inc., Deals By Therapy Area, 2010 to YTD 2016 8
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Synthetic Biologics Completes Acquisition Of C. difficile Infectious Disease Program Of Prev AbR 10
Intrexon Enters into Partnership with Synthetic Biologics 12
Synthetic Biologics Enters Into Agreement With Intrexon To Develop Monoclonal Antibodies For Infectious Diseases 13
Adeona Pharma Enters Into Co-Development Agreement With Intrexon 15
Adeona Pharma Enters Into Co-Development Agreement With Meda 17
Synthetic Biologics Terminates Licensing Agreement with University of California 19
Synthetic Biologics Enters Into Licensing Agreement With Cedars-Sinai Medical Center 21
Synthetic Biologics Raises USD46 Million in Public Offering of Shares 23
Synthetic Biologics to Raise USD20.7 Million in Private Placement of Units 25
Synthetic Biologics Completes Public Offering Of Shares For US$13.2 Million 27
Synthetic Biologics Completes Private Placement Of Common Stock For US$11 Million 28
Adeona Pharma Completes Private Placement Of Shares For US$3.5 Million 30
Adeona Pharma Completes Registered Direct Offering For US$4 Million 32
Adeona Pharma Completes Private Placement Of US$1 Million 34
Hartlab Acquires Adeona Clinical Lab From Synthetic Biologics 36
Synthetic Biologics, Inc., Key Competitors 37
Synthetic Biologics, Inc., Key Employees 38
Synthetic Biologics, Inc., Other Locations 39
Synthetic Biologics, Inc., Subsidiaries 39
List of Figures
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
